Key Development
On August 27, 2026, the Drug Administration of Vietnam (DAV) under the Ministry of Health issued an urgent regulatory directive ordering the immediate nationwide suspension of circulation and comprehensive recall of two production batches of Rolux AF Intimate Hygiene Wash.
The statutory recall was enacted following formal investigative findings from the Police Investigation Agency of Bac Ninh Provincial Police, which officially authenticated that the distributed batches represent counterfeit goods.
Detailed Batch Profile & Involved Corporate Entities:
-
Commercial Product: Rolux AF Intimate Hygiene Wash (Dung dịch vệ sinh phụ nữ Rolux AF).
-
Compromised Counterfeit Batches:
-
Batch 1: Lot No. 08102025 | Mfg Date: Oct 10, 2025 | Exp Date: Oct 10, 2027.
-
Batch 2: Lot No. 09102025 | Mfg Date: Oct 11, 2025.
-
-
Product Marketing Authorization Holder: Evercare Pharmaceutical Cosmetics JSC (Tan Dinh Commune, Bac Ninh Province).
-
Designated Contract Manufacturer: BMP Pharmaceutical JSC (Tan Dinh Commune, Bac Ninh Province).
-
Mandatory Compliance Timeline: The DAV instructed Evercare and BMP to dispatch urgent recall notices across their entire distribution and retail pharmacy networks, secure and quarantine all circulating inventory, and submit a comprehensive reconciliation report to the DAV before September 18, 2026.
Why It Matters
-
Protecting Consumer Health from Toxic & Non-Sterile Formulations: Intimate feminine hygiene washes are applied directly to vulnerable mucosal tissues. Counterfeit cosmetics are typically compounded without cGMP controls, using unverified industrial surfactants, synthetic fragrances, and inappropriate pH balances, posing acute clinical risks of severe contact dermatitis, mucosal ulceration, secondary bacterial/fungal vaginosis, and long-term reproductive complications.
-
Police Investigation & Potential Criminal Liability: The direct involvement and forensic confirmation by the Bac Ninh Provincial Police Investigation Agency highlight the severity of the offense. Manufacturing and distributing counterfeit healthcare products carry statutory criminal liability under Vietnam’s Penal Code for commercial fraud and fake goods production.
-
Activating Provincial Anti-Counterfeit Hotlines Across 63 Provinces: The DAV directed Departments of Health across all provinces and municipalities to alert healthcare facilities and pharmacies, supervise the physical return of non-compliant stock, and establish public hotlines to solicit intelligence on counterfeit, smuggled, and untraceable cosmetics.
Healthcare Insight Analysis
From the perspective of Healthcare Insight, the August 27, 2026 recall directive illustrates Cosmeceutical Anti-Counterfeiting & Regulatory Enforcement.
The enforcement framework establishes three operational governance imperatives:
-
Local Jurisdiction Accountability (Bac Ninh Province): The Bac Ninh Department of Health is mandated to coordinate with provincial police and market surveillance authorities to audit Evercare and BMP on-site, ensuring complete physical impoundment and supervised destruction of the counterfeit inventory.
-
Securing Retail Pharmacies and E-Commerce Outlets: Counterfeit cosmeceuticals frequently penetrate secondary wholesale channels, suburban community pharmacies, and digital storefronts. A formal national recall requires all licensed pharmacies to conduct immediate inventory audits and verify chain-of-custody documentation.
-
Public Transparency & Brand Protection: Broad media disclosure of exact batch numbers and forensic findings empowers end-users to immediately identify and discard illicit bottles, mitigating adverse public health exposure.
Market Implications
-
Mandatory Inventory Audits Across Retail Pharmacies: Community pharmacies, drugstores, and personal care retailers nationwide must immediately inspect stock, halt sales, and isolate Rolux AF batches 08102025 and 09102025.
-
Heightened Scrutiny on Contract Cosmetics Manufacturers (OEM/ODM): Third-party cosmetic formulation plants in northern Vietnam will face increased unannounced inspections regarding raw material sourcing, batch production records, and product self-declaration compliance.
-
Accelerated Adoption of Anti-Counterfeiting Packaging Technologies: Legitimate pharmaceutical and personal care manufacturers will accelerate investments in serialized anti-counterfeit QR codes, tamper-evident seals, and high-security packaging solutions.
Regulatory Enforcement Matrix: Rolux AF Counterfeit Recall (August 2026)
| Regulatory Parameter | Official Data & Forensic Findings | Statutory Scope & Enforcement Mandate |
| Recalled Product | Rolux AF Intimate Hygiene Wash | Personal care & cosmeceutical product. |
| Compromised Batches | Lot 08102025 (Exp: Oct 2027) & Lot 09102025 | Officially confirmed as counterfeit goods. |
| Marketing Entity | Evercare Pharmaceutical Cosmetics JSC (Bac Ninh) | Legally accountable for market distribution. |
| Contract Manufacturer | BMP Pharmaceutical JSC (Bac Ninh) | Listed production site subject to compliance audits. |
| Regulatory Action | Nationwide suspension & mandatory product recall | Quarantine and removal from all retail points. |
| Statutory Deadline | Final report due before September 18, 2026 | Formal submission to the Drug Administration (DAV). |
| Investigative Agency | Bac Ninh Provincial Police Investigation Agency | Criminal investigation and statutory proceedings. |